Oncology Medical News about early-stage breast cancer;partial breast irradiation;dose-dense Coxorubicin and Cyclophosphamide

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer
Journal of Clinical Oncology, 06/10/09

Zellars RC et al. - In a study to determine whether anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) are safe, it was shown that PBI with concurrent dose-dense doxorubicin and cyclophosphamide (ddAC) is feasible, and local/systemic toxicity is acceptable.

Methods

Women with T1-2, N0-1 breast cancer with ≥3 mm lumpectomy margins received PBI (40.5 Gy, 15 daily 2.7-Gy fractions) concurrently with the first 2 of 4 cycles of ddAC (60 and 600 mg/m2 of doxorubicin and cyclophosphamide, respectively, every 14 days with colony-stimulating support).
Primary endpoints were local and systemic toxicity.
Additional systemic therapy was given at the physician's discretion.

Results

27 pts enrolled, but 2 pts did not receive protocol therapy (1 found with additional local disease and 1 withdrew consent).
25 women completed all planned PBI.
4 (16%) of 25 did not complete all ddAC (febrile neutropenia [FN], n=2; diverticulitis and neutropenia, n=1; and social/economic reasons, n=1).
4 of the remaining 21 who completed all ddAC had a cycle delayed (FN, n=1; acute respiratory illness, n=1; foot blisters, n=1; perianal dermatitis, n=1).
There was no grade 3 to 4 anemia or thrombocytopenia.
Grade 3 nonhematologic toxicities (none grade 4) occurred in 28% (7 of 25) of pts (nausea/vomiting, n=3; stomatitis, n=2; contralateral breast abscess, n=1; fatigue, n=1; and cough/bronchospasms, n=1).
observed rate of ≥ grade 2 skin toxicity was 0% (0 of 25).

<< Previous
Infection Control Cutbacks Cost Patients and Hospitals

Next >>
Ki67 expression and docetaxel efficacy in patients with estrogen...